Research Papers:

Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study

Dongmei Ji _, Qiu Li, Junning Cao, Ye Guo, Fangfang Lv, Xiaojian Liu, Biyun Wang, Leiping Wang, Zhiguo Luo, Jianhua Chang, Xianghua Wu and Xiaonan Hong

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:33331-33339. https://doi.org/10.18632/oncotarget.8973

Metrics: PDF 2180 views  |   HTML 1871 views  |   ?  


Dongmei Ji1, Qiu Li2, Junning Cao1, Ye Guo1, Fangfang Lv1, Xiaojian Liu1, Biyun Wang1, Leiping Wang1, Zhiguo Luo1, Jianhua Chang1, Xianghua Wu1, Xiaonan Hong1

1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China

2Department of Medical Oncology, West China Hospital of Medicine, Sichuan University, Chengdu 610041, P.R. China

Correspondence to:

Xianghua Wu, e-mail: [email protected]

Xiaonan Hong, e-mail: [email protected]

Keywords: thalidomide, chop, diffuse large B-cell lymphoma

Received: November 09, 2015     Accepted: April 02, 2016     Published: April 25, 2016


Cyclophosphamide, doxorubicin, vincristine, and prednisolone plus rituximab (R-CHOP) is the standard treatment for patients with diffuse large B cell lymphoma (DLBCL). However, rituximab cannot be popularly applied in a considerable number of patients with DLBCL because of economic reasons. To develop a new regimen to improve the outcome of these patients is extremely important. In our study, sixty five patients with DLBCL were randomly assigned to thalidomide plus CHOP group (n=32) or to CHOP alone group (n=33). Objective response rates (ORR) and complete remission rates (CRR) were 96.7% and 80.6% in T-CHOP group versus 78.9 % and 57.8 % in CHOP group, respectively (P <0.05). At a median follow-up of 96 months, median PFS for T-CHOP group was still not reached yet, and in CHOP group it was 22.9 months (95% CI [0-50.4]). (P=0.163). Median overall survival (OS) for T-CHOP group was also not reached, and the estimated median OS for CHOP group was 83.5 months, the difference of OS between the two groups is not significant (p=0.263). But, in patients with Bcl-2 positive and Bcl-6 negative, the median PFS in T-CHOP group was longer than that in CHOP group (111.0 vs 8.5 months (P=0.017). In addition, thalidomide did not significantly increase the grade 3/4 toxicity of CHOP. We concluded that the addition of thalidomide to the CHOP regimen significantly improved the CRR and showed a trend of improving clinical outcome in patients with DLBCL, especially for patients with Bcl-2 positive and Bcl-6 negative B-cell phenotype, without increased toxicity.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8973